EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDAgreement • August 14th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • Utah
THIS AGREEMENT is entered into on __23 June 2020__ by and between __ Dave Strayer, AIM ImmunoTech Inc. _ (Sponsor) having its principal place of business as detailed above, and Utah State University (USU), a state institution of higher education.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDClinical Trial Agreement • August 14th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT (“Agreement”), made as of the date of last signature (“Effective Date”), by and between ROSWELL PARK CANCER INSTITUTE CORPORATION D/B/A ROSWELL PARK COMPREHENSIVE CANCER CENTER (“Institution”), a New York State public benefit corporation, with its principal office located at Elm and Carlton Streets, Buffalo, NY 14263, employer of, Brahm Segal, MD (“Principal Investigator”), and AIM ImmunoTech Inc. (hereinafter “AIM”), a corporation with its principal place of business at 2117 SW Highway 484, Ocala, Florida 34473. The Institution and AIM together are referred to herein as the Parties.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDMaterial Transfer and Research Agreement • August 14th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Material Transfer and Research Agreement (the “Agreement”) is made as of May 15, 2020, (“Effective Date”) by and between AIM ImmunoTech, Inc. (“AIM”), located at 2117 SW Highway 484, Ocala, FL 34473, and University of Rochester (“Rochester”), having a business address at the Office of Research & Project Administration 518 Hylan Building, Box 270140, Rochester, NY 14627. AIM and Rochester shall be referred to individually as a “party” and together as the “parties.”
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDTransfer and Research Agreement • August 14th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Agreement is made as of June 22, 2020 (“Effective Date”) by and between AIM IMMUNOTECH INC. (“AIM”), a corporation incorporated under the laws of Delaware, having an Offices at 2117 SW Hwy 484 Ocala Fl 34473 as the supplier of the experimental drug Ampligen® and a collaborative group consisting of Japanese National Institute of Infectious Disease (“NIID”) with its address at 4-7-1 Gakuen, Musashimurayama-shi, Tokyo, 208-0011 Japan, and Shionogi & Co., Ltd. (including its affiliates, “Shionogi”) with its address at 1-8, Doshomachi 3-chome Chuo-ku, Osaka 541-0045 Japan (together referred to as the “Companies”). AIM, Shionogi and NIID shall be referred to individually as a “Party” and together as the “Parties.”
